Callan JMB Signs Manufacturing Oversight, Federal Deployment, and Commercialization Agreement of Multi-Asset Therapeutic Pipeline with Attune for Approximately $50 to $75 Million in Total Revenue

Rhea-AI Summary

Callan JMB (NASDAQ:CJMB) signed a strategic teaming agreement with Attune Biotech on Jan 15, 2026 to provide manufacturing oversight, federal deployment coordination, and commercialization support for Attune's multi-asset therapeutic pipeline. The parties expect approximately $50–$75 million in combined revenue over the next 5 years, with Callan JMB's share projected at about $25–$45 million depending on 50% or 60% profit-sharing by contract scope. Callan JMB cites validated surge-readiness capacity (a 500,000-unit simulation), 24-hour emergency deployment capability and Regional CONUS distribution within 48 hours, aiming to accelerate Attune's federal SNS integration and BARDA/DoD/VA procurement readiness.

Positive

• Anticipated combined revenue of $50–$75M over 5 years
• Potential $25–$45M revenue opportunity for Callan JMB
• Validated surge-readiness: 500,000-unit simulation passed federal benchmarks
• 24-hour emergency deployment capability; CONUS regional delivery within 48 hours
• Profit-sharing structured at 50%–60% depending on contract scope

Negative

• Projected revenue is an anticipated range, not guaranteed
• Callan JMB's realized take depends on contract scope and profit-share
• Commercial and federal awards required to convert the $50–$75M projection

News Market Reaction

+275.00% 3051.1x vol

44 alerts

+275.00% News Effect

+371.2% Peak in 2 hr 43 min

+$19M Valuation Impact

$26M Market Cap

3051.1x Rel. Volume

On the day this news was published, CJMB gained 275.00%, reflecting a significant positive market reaction. Argus tracked a peak move of +371.2% during that session. Our momentum scanner triggered 44 alerts that day, indicating elevated trading interest and price volatility. This price movement added approximately $19M to the company's valuation, bringing the market cap to $26M at that time. Trading volume was exceptionally heavy at 3051.1x the daily average, suggesting very strong buying interest.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Agreement revenue range: approximately $50 to $75 million CJMB revenue share: $25 million to $45 million Surge simulation size: 500,000-unit deployment +5 more

8 metrics

Agreement revenue range approximately $50 to $75 million Total combined revenue anticipated over the next 5 years

CJMB revenue share $25 million to $45 million Approximate potential revenue opportunity for Callan JMB over 5 years

Surge simulation size 500,000-unit deployment Late 2024 surge-readiness simulation across six regional SNS sites

Activation benchmark 10-day activation Simulation met federal benchmarks for 10-day activation

Emergency deployment time 24-hour emergency deployment Platform validated for 24-hour emergency deployment

Regional distribution time 48 hours Regional distribution to any CONUS location within 48 hours

Active FDA INDs three active FDA INDs For Lodonal clinical programs with two additional INDs pending

Surge capacity 500,000+ unit surge capacity Validated U.S.-based cGMP production for Lodonal

Market Reality Check

Price: $1.55 Vol: Volume 21,408 vs 20-day a...

low vol

$1.55 Last Close

Volume Volume 21,408 vs 20-day average 64,055 (relative volume 0.33) suggests limited pre-news participation. low

Technical Price at $1.12 trades below 200-day MA at $4.12, near 52-week low $1.0815 and far from 52-week high $7.7599.

Peers on Argus

CJMB showed a -5.88% move while logistics peers were mixed: JYD -2.18%, LSH -4.4...

1 Down

CJMB showed a -5.88% move while logistics peers were mixed: JYD -2.18%, LSH -4.44%, PSIG -0.47%, but NCEW +11.81% and ATXG +3.76%, and only one peer (BTOC) appeared on the momentum scanner. This points to a stock-specific reaction rather than a coordinated sector move.

Historical Context

5 past events · Latest: 2026-01-12 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
2026-01-12	Strategic pivot	Positive	+3.0%	Announced GLP‑1 cold-chain pivot and Texas cGMP facility retrofitting.
2025-11-14	Earnings update	Neutral	+3.6%	Reported Q3 2025 results with higher revenue but wider losses.
2025-11-13	Facility agreement	Positive	-9.2%	Preliminary deal to install oral drug delivery equipment in Texas facility.
2025-11-10	Sector expansion	Positive	-2.5%	Expansion into food sampling logistics via partnership with AI platform Keychain.
2025-10-13	Tech upgrade	Positive	-0.9%	Launched Sentry 4.0 HTML5 temperature monitoring platform for pharma storage.

Pattern Detected

Recent history shows mixed alignment: two positive/neutral news events saw gains, while three operational updates coincided with declines, suggesting frequent divergence between seemingly constructive news and short-term price moves.

Recent Company History

Over the last few months, Callan JMB has reported Q3 2025 financials, expanded into food sampling, upgraded its Sentry 4.0 monitoring platform, and announced a strategic pivot to GLP-1 cold‑chain infrastructure with Texas cGMP retrofitting. Price reactions ranged from modest gains to declines following operational updates. Today’s federal-focused commercialization and oversight agreement with Attune extends this strategy of leveraging regulated logistics capabilities into healthcare and emergency preparedness contracts.

Market Pulse Summary

The stock surged +275.0% in the session following this news. A strong positive reaction aligns with ...

Analysis

The stock surged +275.0% in the session following this news. A strong positive reaction aligns with management’s strategy of leveraging regulated cold‑chain and federal logistics capabilities into higher-value healthcare contracts. The Attune agreement outlines potential combined revenue of $50 to $75 million and a projected $25 to $45 million opportunity for Callan JMB over five years. Investors might weigh this against the company’s history of mixed price responses to operational news and its prior revenue base.

Key Terms

strategic national stockpile, biomedical advanced research and development authority, food and drug administration, cGMP, +4 more

8 terms

strategic national stockpile regulatory

"Strategic National Stockpile deployment coordination—positioning Attune 's pipeline for immediate federal deployment..."

A strategic national stockpile is a government-held reserve of critical medical supplies, medicines, vaccines and equipment kept to respond quickly to public health emergencies. For investors, it matters because government purchases, replenishment schedules and stockpile policies can create sudden demand, long-term contracts or regulatory priorities that directly affect makers, distributors and suppliers of those goods—think of it as a national emergency pantry that can drive corporate revenue and risk.

biomedical advanced research and development authority regulatory

"Biomedical Advanced Research and Development Authority (“BARDA”) contract compliance..."

A biomedical advanced research and development authority is a government agency that funds and guides the late-stage development and manufacturing of drugs, vaccines, diagnostics and other health technologies, especially those needed for public health emergencies. For investors it matters because its contracts, grants or technical support act like a bridge and safety net—reducing development risk, accelerating timelines and creating a more reliable path to revenue for companies working on critical medical products.

food and drug administration regulatory

"Food and Drug Administration (“FDA”) audit readiness and mock inspections..."

A government agency that reviews and regulates medicines, medical devices, food safety, and related products to ensure they are safe and effective for public use. Investors watch its actions like a referee’s calls: approvals, warnings, inspections or recalls can directly affect a product’s ability to reach the market, a company’s sales and costs, and overall business risk and valuation.

cGMP regulatory

"Manufacturing has transitioned to fully U.S.-based cGMP production with 500,000+ unit surge capacity validated."

cGMP (current Good Manufacturing Practice) are government-enforced quality standards that manufacturers must follow to ensure drugs, medical devices, and related products are made consistently, safely, and meet specified quality tests. For investors, cGMP compliance is like a restaurant passing health inspections: it reduces the risk of product recalls, regulatory fines, or production stoppages that can hurt revenue and company value, and it supports market access and long-term trust.

emergency use authorization regulatory

"and is pursuing accelerated regulatory pathways including Emergency Use Authorization, Orphan Drug designation..."

A regulatory emergency use authorization allows a government health agency to temporarily permit the use or sale of a medical product—such as a vaccine, test, or treatment—before full formal approval when there is a public health crisis. For investors, an authorization can rapidly open revenue and market access while carrying higher regulatory and demand risk, like a fast-track pass that speeds a product to customers but may still require further review and can affect a company's valuation and future sales prospects.

orphan drug designation regulatory

"and is pursuing accelerated regulatory pathways including Emergency Use Authorization, Orphan Drug designation..."

Orphan drug designation is a special status given to medicines developed to treat rare diseases affecting only a small number of people. This status often provides benefits like faster approval processes and financial incentives, making it more attractive for companies to develop these drugs. For investors, it signals potential for exclusive market rights and reduced competition, which can impact the drug’s profitability.

priority review vouchers regulatory

"and Priority Review Vouchers. Manufacturing has transitioned to fully U.S.-based cGMP production..."

A priority review voucher is an official token issued by a drug regulator that lets a company move a future drug application to the front of the review line, cutting the time regulators take to decide. It matters to investors because the voucher is often transferable or sellable and can be worth hundreds of millions, acting like a "fast-pass" that speeds a product to market or becomes a one-time cash asset on a company’s balance sheet.

phase 2 medical

"MENK-201: A methionine enkephalin peptide therapeutic with Phase 2 clinical data as salvage therapy..."

Phase 2 is the mid-stage clinical trial where a new drug or treatment is tested in a larger group of patients to see if it works and to keep checking safety after initial human testing. Think of it as a field test that proves whether a product actually delivers its promised benefit. Investors watch Phase 2 closely because its results strongly influence a medicine’s chances of reaching the market, the size of its potential sales, and the company’s valuation.

AI-generated analysis. Not financial advice.

Partnership Leverages Callan JMB's Federal Contract Experience, Cold Chain Infrastructure, and Strategic National Stockpile Relationships to Enable Immediate Deployment Readiness

SPRING BRANCH, TX, Jan. 15, 2026 (GLOBE NEWSWIRE) -- Callan JMB Inc. (NASDAQ: CJMB), (“Callan JMB” or the “Company”), an integrative logistics company empowering the healthcare industry and emergency management agencies through fulfillment, storage, monitoring, and cold chain logistics services, today announced it has signed a strategic teaming agreement with Biostax Corp d/b/a Attune Biotech Inc. (“Attune”), a clinical-stage biopharmaceutical company with a diversified therapeutic pipeline. Callan JMB will serve as independent third-party overseer of Attune 's manufacturing, quality assurance and control, and deployment operations.

Under the agreement, Callan JMB will provide comprehensive federal oversight services, including manufacturing quality assurance and independent batch record review, Biomedical Advanced Research and Development Authority (“BARDA”) contract compliance, Food and Drug Administration (“FDA”) audit readiness and mock inspections, milestone tracking, and federal reporting, supply chain governance and supplier qualification, and Strategic National Stockpile deployment coordination—positioning Attune 's pipeline for immediate federal deployment through Callan JMB's existing government infrastructure.

Through its Senior Leadership and its subsidiary Coldchain Technology Services, Callan JMB has managed national stockpile assets for BARDA, Strategic National Stockpile (SNS), Department of Defense (“DoD”), and Department of Veterans Affairs (“VA”). Callan JMB brings immediate deployment capability through existing federal infrastructure, bypassing the typical 27-48 month logistics setup timeline for new pharmaceutical products.

In late 2024, Attune and Coldchain Technology Services successfully completed a surge-readiness simulation replicating 500,000-unit deployment across six regional SNS sites, meeting federal benchmarks for 10-day activation while stress-testing full DSCSA, GDP, and DEA compliance requirements. The platform is now validated for 24-hour emergency deployment and regional distribution to any CONUS location within 48 hours.

Under the terms of the teaming agreement, the parties anticipate generating approximately $50 to $75 million in total combined revenue over the next 5 years, driven by opportunities across both federal and commercial markets. Revenues generated through the agreement will be shared through a profit-sharing platform structured at either 50% or 60%, depending on contract and scope. This represents an approximate potential revenue opportunity of $25 million to $45 million for Callan JMB over the next 5 years.

"This teaming agreement represents a significant expansion of Callan JMB's role in the federal medical countermeasure ecosystem," said Wayne Williams, Founder and Chief Executive Officer of Callan JMB. "Our team brings over 20 years of experience managing federal health programs, BARDA contracts, and Strategic National Stockpile operations. Through our existing knowledge and experience, as well as our infrastructure with BARDA/ASPR, DoD, and VA, we can provide Attune immediate deployment capabilities that would typically take new manufacturers years to establish. Our oversight services, from manufacturing quality assurance to FDA audit readiness to emergency deployment protocols, ensure that Attune's pipeline meets the rigorous standards required for federal procurement. When national preparedness depends on having the right medicine in the right place at the right time, this is exactly what we do."

"Partnering with Callan JMB fundamentally accelerates our path to federal deployment," said Noreen Griffin, Chief Executive Officer of Attune. "Having successfully completed our surge-readiness validation with Coldchain Technology Services, our manufacturing platform is now positioned for immediate SNS integration. Wayne Williams' direct experience with BARDA contracts, FDA compliance, and DoD/VA pharmaceutical services provides exactly the federal oversight and credibility our pipeline requires. With Lodonal^™, MENK-201, and Cytocide-100^™ each addressing critical unmet needs in pandemic preparedness, veteran health, and emergency response, Callan JMB's existing federal relationships and proven infrastructure make them the ideal partner to bring our therapies to the patients who need them most."

Attune's pipeline includes multiple clinical and commercial-stage assets addressing significant unmet medical needs:

Lodonal^™ (JKB-122): A first-in-class TLR4 antagonist for immune restoration, currently in development across five parallel clinical programs including Long COVID, HIV immune non-responders, autoimmune hepatitis, metabolic liver diseases (MASLD/MASH), and chronic immune pain. The company holds three active FDA INDs with two additional INDs pending and is pursuing accelerated regulatory pathways including Emergency Use Authorization, Orphan Drug designation, and Priority Review Vouchers. Manufacturing has transitioned to fully U.S.-based cGMP production with 500,000+ unit surge capacity validated.

MENK-201: A methionine enkephalin peptide therapeutic with Phase 2 clinical data as salvage therapy in HIV patients and pancreatic cancer. MENK-201 represents an important addition to Attune 's immune modulation platform with demonstrated clinical activity in difficult-to-treat patient populations.

Cytocide-100^™: A patented, ultra-low pH antimicrobial platform with broad-spectrum biocidal activity against bacteria, viruses, fungi, biofilms, and mycobacteria. FDA monograph-compliant for OTC applications, including wound care, dermatology, and antiseptic use, with EPA state approvals for environmental sanitation and is positioned for a BARDA partnership as a field-ready wound care and emergency sanitation solution.

About Callan JMB Inc.
Callan JMB Inc. is a vertically integrated logistics company empowering the healthcare industry and emergency management agencies through fulfillment, storage, monitoring, and cold chain logistics services to secure medical materials and protect patients and communities with compliant, safe, and effective medicines. Our combined expertise in supply chain logistics, thermodynamics, biologics, inventory management, regulatory compliance and emergency preparedness is unparalleled in the industry. We offer a gold standard in client experience with customizable interfaces, next-level reliability in shipping and environmental sustainability in our specialty packaging.

About Biostax Corp d/b/a Attune Biotech Inc.
Biostax Corp d/b/a Attune Biotech Inc. (“Attune”) is a clinical-stage biotechnology company with a diversified pipeline of therapeutic assets and fully U.S.-based cGMP manufacturing capability. The company's lead program, Lodonal^™ (JKB-122), is a first-in-class TLR4 antagonist designed to restore immune homeostasis, supported by 150,000+ patient-years of safety data across five parallel clinical programs. Additional pipeline assets include MENK-201, a peptide therapeutic with Phase 2 data in HIV and oncology, and Cytocide-100^™ (pHL 100), an FDA monograph-compliant antimicrobial platform. Attune leverages 505(b)(2) regulatory strategies, its proprietary STARR AI^™ digital trial platform, and strategic public-private partnerships to advance capital-efficient, patient-centric drug development. For more information, visit https://attunebio.com/.

Forward-Looking Statement
This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) (which Sections were adopted as part of the Private Securities Litigation Reform Act of 1995). Statements preceded by, followed by or that otherwise include the words “believe,” “anticipate,” “estimate,” “expect,” “intend,” “plan,” “project,” “prospects,” “outlook,” and similar words or expressions, or future or conditional verbs, such as “will,” “should,” “would,” “may,” and “could,” are generally forward-looking in nature and not historical facts. These forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the Company’s actual results, performance, or achievements to be materially different from any anticipated results, performance, or achievements for many reasons. The Company disclaims any intention to, and undertakes no obligation to, revise any forward-looking statements, whether as a result of new information, a future event, or otherwise. For additional risks and uncertainties that could impact the Company’s forward-looking statements, please see the Company’s Registration Statement Under the Securities Act of 1933 on Form S-1, including but not limited to the discussion under “Risk Factors” therein, which the Company filed with the SEC and which may be viewed at http://www.sec.gov/.

Investor Contacts:
Valter Pinto, Managing Director
KCSA Strategic Communications
CallanJMB@kcsa.com
212.896.1254

FAQ

What revenue does Callan JMB (CJMB) expect from the Attune teaming agreement announced Jan 15, 2026?

The parties anticipate approximately $50–$75 million combined over the next 5 years, with Callan JMB's potential share of about $25–$45 million.

How will the CJMB–Attune agreement speed federal deployment for Attune therapies?

Callan JMB will provide federal oversight, SNS coordination, BARDA contract compliance, FDA audit readiness, and supply chain governance to enable immediate deployment readiness.

What surge-readiness capability did Callan JMB validate with Attune prior to the Jan 15, 2026 agreement?

A late-2024 simulation replicated a 500,000-unit deployment across six regional SNS sites, meeting 10-day activation benchmarks and validating 24-hour emergency deployment.

How is revenue split under the Callan JMB and Attune profit-sharing model?

Revenues generated under the teaming agreement will be shared via a profit-sharing platform set at either 50% or 60%, depending on contract and scope.

Which Attune assets are referenced in the Jan 15, 2026 teaming agreement with CJMB?

The announcement cites Lodonal (JKB-122), MENK-201, and Cytocide-100 as key pipeline assets positioned for federal deployment and emergency response use.

What federal customers and programs has Callan JMB managed relevant to this agreement?

Callan JMB and its Coldchain Technology Services subsidiary have managed assets for BARDA, Strategic National Stockpile, Department of Defense, and Department of Veterans Affairs.